Trading Signals: FOLD Stock Price Prediction and Forecast (Thu. May. 31, 2007 - Fri. Dec. 22, 2023)(Amicus Therapeutics Inc)
| FOLD latest price $9.5250 (0.11%) ($9.5250 - $9.5250) on Fri. Mar. 26, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 4.92% (three month average) | RSI | 43 | Latest Price | $9.5250(0.11%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | FOLD declines -1.3% a day on average for past five trading days. | Weekly Trend | FOLD declines -3.4% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support FOLD advance at 0% a week (0% probability) IBB(57%) IWO(54%) XBI(51%) IWC(50%) IWM(50%) | Factors Impacting FOLD price | FOLD will decline at least -2.46% in a week (0% probabilities). VIXM(-30%) VXX(-14%) UUP(-12%) UNG(-6%) IGOV(-4%) | | | | | Relative Volatility | | | | Market Trend Strength | -2.46% (StdDev 4.92%) | Hourly BBV | -0.4 () | Intraday Trend | 0% | | | |
|
1 - 5 Day Possible Target | $-2.28(-123.94%) | Resistance Level | $10.37 | 5 Day Moving Average | $9.82(-3%) | 10 Day Moving Average | $10.1(-5.69%) | 20 Day Moving Average | $10.37(-8.15%) | To recent high | -60.1% | To recent low | 1% | Market Cap | $2.46b | | | | Amicus Therapeutics, Inc. is a biotechnology company focused on discovering, developing, and delivering medicines for people living with rare metabolic diseases. The company is committed to advancing and expanding a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. Amicus Therapeutics has a portfolio of product opportunities including the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants; a novel, clinical-stage, treatment paradigm for Pompe disease; and a rare disease gene therapy portfolio. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ. |